Research Analysts Set Expectations for TSE:MDP Q1 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Raymond James lifted their Q1 2026 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Monday, March 17th. Raymond James analyst M. Freeman now anticipates that the company will earn ($0.20) per share for the quarter, up from their previous forecast of ($0.26). Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ FY2026 earnings at ($0.46) EPS.

Several other equities analysts have also issued reports on the stock. Stifel Canada lowered shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Ventum Financial boosted their price target on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a report on Thursday, January 30th. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from C$6.00 to C$3.45 in a report on Friday, February 7th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of C$5.49.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$2.55 on Wednesday. The company has a fifty day moving average price of C$3.38 and a two-hundred day moving average price of C$2.92. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm has a market capitalization of C$57.09 million, a PE ratio of 12.19 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.